益生菌辅助三联疗法治疗小儿慢性胃炎合并幽门螺杆菌感染的临床疗效观察  

Observation on clinical efficacy of probiotic as an adjuvant to triple therapy in the treatment of chronic gastritis complicated with Helicobacter pylori infection in children

作　　者：吴清秀 WU Qing-xiu(Department of Pediatrics,Linshu County Maternal and Child Health and Family Planning Service Center(Linshu County Maternal and Child Health Hospital),Linyi 276700,China)

机构地区：[1]临沭县妇幼保健计划生育服务中心儿科(临沭县妇幼保健院),276700

出　　处：《中国现代药物应用》2022年第22期27-31,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析益生菌(酪酸梭菌活菌片)辅助三联疗法治疗小儿慢性胃炎合并幽门螺杆菌(Hp)感染的临床效果。方法62例慢性胃炎合并Hp感染患儿,按随机数字表法分为对照组和研究组,每组31例。对照组患儿给予三联疗法治疗,研究组患儿在对照组基础上联合使用益生菌治疗。比较两组治疗前后胃肠道症状评定量表(GSRS)评分和胃肠道症状积分问卷(GIS)评分、炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)]、肠道菌群指标[肠杆菌、乳杆菌、酵母菌、肠球菌、双歧杆菌菌落数和双歧杆菌值/肠杆菌值(B/E)]及不良反应发生情况、Hp转阴率、复发情况。结果治疗前,两组患儿的GSRS、GIS评分对比,差异均无统计学意义(P>0.05);治疗后,研究组患儿的GSRS评分(17.43±3.71)分、GIS评分(11.30±3.52)分均低于对照组的(28.26±4.08)、(20.27±3.91)分,差异有统计学意义(P<0.05)。治疗前,两组患儿的IL-6、IL-8、TNF-α水平对比,差异均无统计学意义(P>0.05);治疗后,研究组患儿的IL-6、IL-8、TNF-α分别为(5.03±0.71)、(6.41±1.11)、(7.74±1.09)pg/ml,均低于对照组的(7.82±1.14)、(12.32±3.05)、(12.39±3.51)pg/ml,差异有统计学意义(P<0.05)。治疗前,两组患儿的肠杆菌、肠球菌、乳杆菌、双歧杆菌、酵母菌菌落数和B/E对比,差异均无统计学意义(P>0.05)。治疗后,研究组患儿的肠球菌、乳杆菌、双歧杆菌菌落数和B/E均优于对照组,差异有统计学意义(P<0.05);两组肠杆菌、酵母菌菌落数比较差异无统计学意义(P>0.05)。研究组患儿不良反应发生率为9.68%,与对照组的12.90%对比,差异无统计学意义(P>0.05)。研究组患儿Hp转阴率93.55%高于对照组的67.74%,随访6个月复发率3.23%低于对照组的25.81%,差异有统计学意义(P<0.05)。结论临床采用益生菌辅助三联疗法治疗小儿慢性胃炎合并Hp感染,能改善胃肠功能及肠道菌群,还能降低患儿�Objective To analyze the clinical effect of probiotic(clostridium butyricum tablets)as an adjuvant to triple therapy in the treatment of chronic gastritis complicated with Helicobacter pylori(Hp)infection in children.Methods A total of 62 children with chronic gastritis and Hp infection were divided into control group and research group according to random numerical table,with 31 cases in each group.Children in the control group were treated with triple therapy,and children in the research group were treated with probiotics on the basis of the control group.Both groups were compared in terms of gastrointestinal symptom rating scale(GSRS)score and gastrointestinal symptom(GIS)score,inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)],the intestinal flora indexes[number of Enterobacter,Lactobacillus,Yeast,Enterococcus,Bifidobacterium colonies and Bifidobacterium value/Enterobacter value(B/E)]before and after treatment,the occurrence of adverse reactions,the negative-conversion rate of Hp,and recurrence.Results Before treatment,there was no statistically significant difference in GSRS and GIS scores between the two groups(P>0.05).After treatment,the GSRS score(17.43±3.71)points and GIS score(11.30±3.52)points of the research group were lower than(28.26±4.08)and(20.27±3.91)points of the control group,and the differences were all statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of IL-6,IL-8 and TNF-αbetween the two groups(P>0.05).After treatment,the levels of IL-6,IL-8,and TNF-αin the research group were(5.03±0.71),(6.41±1.11),and(7.74±1.09)pg/ml,which were lower than(7.82±1.14),(12.32±3.05),and(12.39±3.51)pg/ml in the control group,and the differences were all statistically significant(P<0.05).Before treatment,there was no statistically significant difference in number of Enterobacter,Enterococcus,Lactobacillus,Bifidobacterium and yeast colonies and B/E between the two groups(P>0.05).After treatment

关 键 词：益生菌 酪酸梭菌活菌片 三联疗法 小儿慢性胃炎合并幽门螺杆菌感染 肠道菌群 炎性因子 

分 类 号：R725.7[医药卫生—儿科]